TERF2 Antibody
| Code | Size | Price |
|---|
| PSI-7727-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7727-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Documents
Further Information
Additional Names:
TERF2 Antibody: TRF2, TRBF2, TRF2, Telomeric repeat-binding factor 2, TTAGGG repeat-binding factor 2
Application Note:
TERF2 antibody can be used for detection of TERF2 by Western blot at 1 - 2 μg/ml. Antibody can also be used for Immunohistochemistry at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
The telomeric repeat binding factor family (TERF1 and TERF2) plays a key role in cellular immortalization and cellular senescence (1). TERF2, as a component of the telomere nucleoprotein complex, is present at telomeres in metaphase of the cell cycle (2). TERF2 is a second negative regulator of telomere length and binds as a dimer to TTAGGG repeats at ends of chromosomes (telomeres), where it blocks inappropriate activation of the ATM/p53 pathway (2,3). TERF1 negatively regulates telomere elongation, while TERF2 protects the chromosome ends by inhibiting end-to-end fusions. Down-regulation of TRF expression in tumor cells may contribute to cell immortalization and malignant progression (4,5).
Background References:
- Broccoli D, Smogorzewska A, Chong L, et al. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat. Genet. 1997; 17:231-5.
- Bilaud T, Brun C, Ancelin K, et al. Telomeric localization of TRF2, a novel human telobox protein. Nat. Genet. 1997; 17:236-9.
- van Steensel B and Smogorzewska A. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92:401-13.
- Matsutani N, Yokozaki H, Tahara E, et al. Expression of TRF1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int. J. Oncol. 2001; 19:507-12.
Buffer:
TERF2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (92%)
Immunogen:
TERF2 antibody was raised against a 17 amino acid peptide near the amino terminus of human TERF2.
The immunogen is located within the first 50 amino acids of TERF2.
The immunogen is located within the first 50 amino acids of TERF2.
NCBI Gene ID #:
7014
NCBI Official Name:
telomeric repeat binding factor 2
NCBI Official Symbol:
TERF2
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 60 kDa
Observed: 69 kDa
Observed: 69 kDa
Protein Accession #:
NP_005643
Protein GI Number:
429535832
Purification:
TERF2 antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer, Cell Cycle
SPECIFICITY:
TERF2 antibody is human specific.
Swissprot #:
Q15554
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | TERF2 Peptide | PSI-7727P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|